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Abstract: Repeat hospitalization due to acute heart failure (HF) is a
global public health problem that markedly impacts on health resource
use. Identifying novel predictors of rehospitalization would help phys-
icians to determine the optimal postdischarge plan for preventing HF
rehospitalization. Nonalcoholic fatty liver disease (NAFLD) is an
emerging risk factor for many heart diseases, including HF.We assessed
whether NAFLD at hospital admission predicts 1-year all-cause rehos-
pitalization in patients with acute HF.
We enrolled all patients consecutively admitted for acute HF to our
General Medicine Division, from January 2013 to April 2014, after
excluding patients with acute myocardial infarction, severe heart valve
diseases, malignancy, known liver diseases, and those with volume
overload related to extracardiac causes. NAFLD was diagnosed by
ultrasonography and exclusion of competing etiologies. The primary
outcome of the study was the 1-year all-cause rehospitalization rate.
Among the 107 patients enrolled in the study, the cumulativecomo Zoppini, MD ardo, MD,
B, BCh, PhD, and Giovanni Targher, MD
NAFLD (58% vs 21% at 1 y; P< 0.001 by the log-rank test). Cox
regression analysis revealed that NAFLDwas associated with a 5.5-fold
increased risk of rehospitalization (adjusted hazard ratio 5.56, 95%
confidence interval 2.46–12.1, P< 0.001) after adjustment for multiple
HF risk factors and potential confounders.
In conclusion, NAFLD was independently associated with higher 1-
year rehospitalization in patients hospitalized for acute HF.
(Medicine 95(7):e2760)
Abbreviations: BMI = body mass index, CHD = coronary heart
disease, CKD = chronic kidney disease, COPD = chronic
obstructive pulmonary disease, EF = ejection fraction, GGT =
gamma-glutamyltransferase, HF = heart failure, LV = left
ventricular, NAFLD = nonalcoholic fatty liver disease, NT-
proBNP = NT-probrain natriuretic peptide.
INTRODUCTION
A pproximately 1% to 2% of the adult population in devel-oped countries has heart failure (HF), with the prevalence
rising to10% among persons 70 years of age or older.1 Before
1990 (the modern era for treatment of HF) 60% to 70% of
patients died within 5 years of diagnosis of HF. Admission to
the hospital with worsening symptoms was a frequent occur-
rence, causing considerable distress to patients and their
relatives. Effective treatment has decreased overall hospitaliz-
ation rates and improved survival from HF.1 However, although
some progress has been made in improving survival among
patients hospitalized with HF, the rates of rehospitalization
continue to rise dramatically, and approach 30% to 40% within
2 to 3 months of the hospital discharge.2 These unacceptably
high rehospitalization rates not only drive burgeoning costs but
also provide a signal that current management approaches to HF
are less than optimal. Among ambulatory patients with chronic
HF, hospital admission is one of the strongest prognostic
predictors for increased mortality. Unplanned hospital read-
missions also create a huge financial burden for health care
organizations and insurers, and HF is the largest contributor to
the huge annual Medicare bill of $17.4 billion.2,3 Consequently,
reducing the rates of rehospitalization from HF has become a
priority for policymakers and health care professionals not only
to improve quality of care but also to markedly reduce costs.
Identifying novel predictors of hospital readmission among
patients with acute HF would help physicians to improve risk
stratification and help to determine the optimal postdischarge
plan for preventing hospital readmission, thus contributing toosts.
de, it has become increasingly clear that
er disease (NAFLD) is a multisystem
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the vascular system and the heart.4,5 Accumulating evidence
suggests that patients with NAFLD have early changes in
cardiac substrate metabolism, producing myocardial functional,
and structural and arrhythmic consequences (e.g., cardiac dys-
function/hypertrophy and atrial fibrillation) that are potentially
linked to an increased risk of incident HF in patients with
NAFLD.5–7 Consistently, some community-based cohort stu-
dies have shown that moderately elevated levels of serum
gamma-glutamyltransferase (GGT), which are surrogate mar-
kers of underlying NAFLD and atherosclerosis, are indepen-
dently associated with an increased risk of incident HF.8–10
Moreover, in a population-based, cross-sectional study of
middle-aged adults, VanWagner et al11 reported that NAFLD
is independently associated with subclinical myocardial remo-
deling and dysfunction, thus providing further pathophysiolo-
gical insight into the potential link between NAFLD andHF. All
of these findings clearly suggest that NAFLD could be, at least
in part, implicated in HF pathophysiology and could be also a
predictor for HF hospital readmissions.
On the basis of these findings, we hypothesized that
patients with NAFLD and acute HF might be prone to excess
rehospitalization rates. To our knowledge, no data are currently
available regarding the association between NAFLD and hos-
pital readmission rates among patients hospitalized for
acute HF.
Therefore, in this prospective, observational study of
patients requiring hospital admission for acute HF, we sought
to determine whether the presence of ultrasound-diagnosed
NAFLD was associated with higher rates of 1-year rehospita-
lization during the first year of follow-up.
METHODS
Patients
In this study, we enrolled all white patients consecutively
admitted with a diagnosis of acute HF to the Division of General
Medicine at the ‘‘Sacro Cuore’’ Hospital of Negrar (Verona)
during the period between January 2013 and April 2014
(n¼ 136). All patients aged 18 years or older were initially
eligible for the study if they had a confirmed clinical diagnosis
of acute HF (de novo or preexisting HF). In agreement with the
2012 European Society of Cardiology guidelines,1 the clinical
diagnosis of acute HF at hospital admission was based on the
presence of typical signs and symptoms of acute HF (e.g.,
breathlessness, orthopnea, paroxysmal nocturnal dyspnea, acute
pulmonary edema, jugular venous distension, and peripheral
edema), increased levels of NT-probrain natriuretic peptide
(NT-proBNP), and also radiographic findings of acute HF
(e.g., pulmonary congestion/oedema and cardiomegaly).
As detailed in Figure 1, for the purpose of this study, we
excluded the following: patients with acute myocardial infarc-
tion, acute cardiac tamponade, and those with volume overload
related to decompensated cirrhosis, end-stage kidney disease,
and other extracardiac causes; patients with severe heart valve
diseases (severe aortic stenosis and severe mitral stenosis or
regurgitation) or heart valve surgery; patients with a documen-
ted history of malignancy, cirrhosis, or other known causes of
chronic liver diseases, including hemochromatosis, viral
hepatitis due to B and C viruses, and excessive alcohol con-
Valbusa et alsumption (defined as>20 g/d for women and>30 g/d of alcohol
intake for men, respectively); and thosewho died during the first
hospital admission (in-hospital death). On the basis of these
2 | www.md-journal.comcriteria, 107 patients hospitalized for acute HFwere identified at
baseline, and these patients were included in the final analysis.
The local Ethics Committee approved the study protocol, and all
participants gave their informed consent.
Clinical and Laboratory Data
A detailed clinical history was recorded in each patient.
Body mass index (BMI) was measured as kilograms divided by
the square of height in meters. Blood pressure was measured
with a standard mercury sphygmomanometer (at the right upper
arm using an appropriate cuff size) after the patient had been
seated quietly for at least 5minutes. Patients were considered to
have hypertension if their blood pressure was 140/90mm Hg
or if they were taking any antihypertensive drugs.
Venous blood samples were drawn in the morning after
an overnight fast. Serum liver enzymes, creatinine (measured
using a Jaffe´ rate-blanked and compensated assay), lipids,
and other biochemical blood measurements were determined
by standard laboratory procedures. Most participants had
serum liver enzyme levels within the reference ranges in
our laboratory, which for serum aminotransferases were 10 to
40U/L for women and 10 to 50 U/L for men, respectively.
Low-density lipoprotein (LDL)-cholesterol was calculated
using the Friedewald equation. Glomerular filtration rate
(eGFR) was estimated by the 4-variable Modification of
Diet in Renal Disease (MDRD) study equation.12 Plasma
levels of NT-proBNP were measured by a chemiluminescent
immunoassay method.
Presence of coronary heart disease (CHD)was defined as a
documented history of myocardial infarction, angina, or cor-
onary revascularization procedures (ie, coronary artery bypass
grafts, percutaneous transluminal coronary angioplasty). Pre-
sence of peripheral artery disease (ie, intermittent claudication,
rest pain, and lower-extremity revascularization procedures)
was based on medical history and examination, and was
confirmed by reviewing hospital medical records of the
patients, including radiology imaging results. Chronic kidney
disease (CKD) was defined as the presence of eGFRMDRD
<60mL/min/1.73m2.12 Presence of chronic obstructive pul-
monary disease (COPD) was confirmed by reviewing medical
records of the hospital, including diagnostic symptoms pat-
terns, and results of lung function tests. The diagnosis of
persistent or permanent atrial fibrillation was made on the
FIGURE 1. Details of the study design.basis of standard 12-lead electrocardiograms and medical
history (from reviewing hospital and physician charts from
all patients).
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Conventional Echocardiography and Liver
Ultrasonography
Conventional transthoracic echocardiography, which was
performed in all patients by experienced cardiologists (blinded
to the participants’ clinical details), was used to measure left
ventricular (LV) diameters and wall thicknesses according to
international standard criteria.13 LV end-diastolic and end-sys-
tolic volumes and ejection fraction at rest were measured at the
apical 4 and 2-chamber views (by modified Simpson rule).13
Liver ultrasonography was performed in all patients by
experienced radiologists, who were blinded to the participants’
details. Fatty liver was diagnosed on the basis of characteristic
ultrasonographic features, that is, diffuse hyperechogenicity of the
liver relative to the cortex of the right kidney, ultrasound beam
attenuation, and poor visualization of both intrahepatic vessel
walls anddiaphragm.14 It isknown that liverultrasonographyhasa
good sensitivity and specificity for detecting moderate and severe
fatty liver (90%–95%), but its sensitivity is reduced when the
hepatic fat infiltration identified by liver biopsy is <20%.14
Semiquantitative ultrasonographic scoring for the degree of fatty
liver (mild, moderate, or severe) was not available in this study.
Statistical Analysis
Data are expressed as meansSD, medians, and inter-
quartile range (IQR) or percentages. The primary outcome of
the study was the 1-year all-cause rehospitalization rate. Rehos-
pitalization data were obtained from either reviewing the
patients’ hospital records or contacting the patients’ physician
and the referring cardiologist, or contacting directly the patients.
No data were recorded about the mortality rate after discharge
from the hospital.
Differences in baseline clinical and biochemical charac-
teristics among patients stratified by 1-year rehospitalization
status at follow-up were tested with the unpaired t test for
normally distributed variables and the Kruskal-Wallis test for
nonnormally distributed variables. The chi-square test was used
for categorical variables to study differences in proportions or
percentages between the 2 groups of patients.
Univariate survival analysis was performed by the Kaplan-
Meier analysis, and the overall significance was calculated by
the log-rank test. Cox regression analysis was used to examine
the association between fatty liver status at baseline and 1-year
rehospitalization rates after adjustment for potential confound-
ing variables. The model assumptions for the Cox proportional-
hazard regression models were checked by visual inspection of
proportional hazard assumption, Schoenfeld residuals, and
covariance matrix. Four forced-entry Cox regression models
were performed: an unadjusted model; a model adjusted for age
and sex (model 1); a model adjusted for age, sex, eGFRMDRD,
and serum GGT levels (model 2); and, finally, a regression
model additionally adjusted for baseline NT-proBNP levels, LV
ejection fraction, BMI, preexisting diabetes, and atrial fibrilla-
tion (model 3). The covariates included in these multivariable
Cox regression models were chosen as potential confounding
factors on the basis of their significance in univariable analyses
or on the basis of their biologic plausibility. Results of Cox
proportional-hazard models were presented as hazard ratios
(HRs) and 95% confidence intervals (CIs). P values <0.05
were considered statistically significant.
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Overall, the 107 (49 men and 58 women) patients with
acute HF included in the study had a mean age of approximately
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.80 years, 59.8% had CKD, 51.4% had permanent/persistent
atrial fibrillation, 37.4% had CHD, 43% had established dia-
betes, and 21.5% had a LV ejection fraction 35%.
In the whole cohort of patients, the rehospitalizations at 1
year (almost 97% of cardiac etiology; only 1 patient was
readmitted for causes that were not related to HF) occurred
in 41 (38.3%) patients. The overall cumulative rehospitalization
rate was 12.1% (n¼ 13) at 1 month, 25.2% (n¼ 27) at 3 months,
29.9% (n¼ 32) at 6 months, and 38.3% (n¼ 41) at 1 year. In the
whole cohort, the prevalence of NAFLD diagnosed on ultra-
sonography was 46.7% (n¼ 50).
The baseline characteristics of the cohort of patients
stratified by rehospitalization status during follow-up are shown
in Table 1. At baseline, patients who had been hospitalized
during the follow-up period had significantly lower eGFR
values and higher serum GGT and aminotransferase concen-
trations than those not requiring rehospitalization. They also
tended to have a higher prevalence of atrial fibrillation, and
were more likely to be treated with spironolactone. At baseline,
age, sex, body weight, BMI, heart rate, smoking history,
systolic/diastolic blood pressure, pulse pressure, plasma NT-
proBNP levels, LV ejection fraction, prior diabetes, COPD,
CHD/angina, peripheral artery disease, use of many ‘‘cardio-
vascular’’ medications (including also the use of Angiotensin
converting enzyme [ACE]-inhibitors, sartans, beta-blockers,
furosemide, amiodarone, and anticoagulants), and hospital
length of stay did not differ significantly between the 2 groups
of patients. Notably, the prevalence of NAFLD at baseline was
markedly higher in patients with rehospitalization at follow-up
than in those without (70.7% vs 31.8%; P< 0.001).
The cumulative proportions of patients with rehospitaliza-
tion at 1 year by NAFLD status are shown in Figure 2. The
Kaplan–Meier analysis revealed that approximately 60% of
patients with NAFLD at baseline were readmitted to the hospital
at 1 year versus only approximately 20% of those without
NAFLD (P< 0.001 for the difference by the log-rank test).
As shown in Table 2, in univariable Cox regression
analysis, the presence of NAFLD was associated with a 3.7
higher rate of 1-year all-cause rehospitalization (P< 0.001). At
multivariable Cox regression analysis (as also shown in
Table 2), the strong association between NAFLD and 1-year
rehospitalization rates was little affected by adjustment for sex
and age (model 1). Further adjustment for eGFR, BMI, serum
GGT levels, NT-proBNP levels, LV ejection fraction, preexist-
ing diabetes, and atrial fibrillation did not weaken the signifi-
cant association between NAFLD and 1-year rehospitalization
(models 2 and 3). Of note, other variables independently
associated with higher 1-year rehospitalization were male
sex, higher GGT levels, and lower baseline eGFRMDRD. Almost
identical results were found when we additionally adjusted for
the use of ACE-inhibitors/sartans, beta-blockers, spironolac-
tone, warfarin, and amiodarone at baseline (adjusted HR 6.25,
95% CI 2.65–14.3, P¼ 0.0015).
We also conducted sensitivity analyses to evaluate the
robustness of our findings. Figure 3 shows the association
between NAFLD and 1-year all-cause rehospitalization rates
in subgroup analyses. Notably, the significant association
between NAFLD and 1-year rehospitalizations was consistently
demonstrated in all subgroups examined, except for a borderline
significance among those with LV ejection fraction 35%,
possibly due to a (relatively) low number of patients in
Fatty Liver and Heart Failure Rehospitalizationthis subgroup.
Interestingly, NAFLD was also associated with higher
1-year rehospitalization rates after excluding either those with
www.md-journal.com | 3
TABLE 1. Baseline Clinical Characteristics of Hospitalized Patients With Acute HF Stratified By 1-year All-cause Rehospitalization
Status at Follow-up
Without Rehospitalization
(n¼ 66)
With Rehospitalization
(n¼ 41) P
Male sex, % 46.9 (n¼ 31) 43.9 (n¼ 18) 0.76
Age, y 79.6 10.7 81.9 9.6 0.25
Body weight, kg 75.7 20.1 78.2 23.2 0.56
Body mass index, kg/m2 27.5 4.2 28.6 4.4 0.58
Heart rate, bpm 82.9 19.1 80.4 19.7 0.52
Smoking history, % 18.2 (n¼ 12) 19.5 (n¼ 8) 0.86
Systolic blood pressure, mm Hg 132.6 20.7 130.1 24.4 0.58
Diastolic blood pressure, mm Hg 76.3 13.1 74.6 11.7 0.51
Pulse pressure, mm Hg 56.3 18.5 55.5 18.7 0.83
eGFRMDRD, mL/min/1.73m
2 65.1 32.3 49.1 26.5 <0.01
GGT, U/L 45 (24–75) 69 (29–108) <0.05
AST, U/L 22 (18–31) 27 (20–38) <0.05
ALT, U/L 19 (12–31) 20 (14–33) 0.07
NT-probrain natriuretic peptide, pg/mL 716 (379–1451) 834 (343–1646) 0.76
LV ejection fraction, % 50 (37–60) 50 (30–57) 0.48
LV ejection fraction 35, % 16.7 (n¼ 11) 29.3 (n¼ 12) 0.15
Diabetes, % 37.9 (n¼ 25) 51.2 (n¼ 21) 0.18
Chronic obstructive pulmonary disease, % 18.2 (n¼ 12) 19.5 (n¼ 8) 0.86
CHD, % 37.9 (n¼ 25) 36.6 (n¼ 15) 0.89
Stroke, % 4.5 (n¼ 3) 9.7 (n¼ 4) 0.30
Peripheral artery disease, % 15.2 (n¼ 10) 17.1 (n¼ 7) 0.79
Atrial fibrillation, % 43.9 (n¼ 29) 63.4 (n¼ 26) 0.052
ACE-inhibitors/ARB users, % 63.6 (n¼ 42) 51.2 (n¼ 21) 0.20
Furosemide users, % 98.5 (n¼ 65) 97.5 (n¼ 40) 0.73
Spironolactone users, % 39.4 (n¼ 26) 58.5 (n¼ 24) 0.06
Beta-blocker users, % 63.6 (n¼ 42) 68.3 (n¼ 28) 0.62
Digoxin users, % 13.6 (n¼ 9) 9.7 (n¼ 4) 0.54
Amiodarone users, % 3.0 (n¼ 2) 2.4 (n¼ 1) 0.19
Antiplatelet drug users, % 51.5 (n¼ 34) 56.1 (n¼ 23) 0.58
Oral anticoagulant users, % 34.8 (n¼ 23) 39.0 (n¼ 16) 0.66
Hospital stay, d 11.3 5.1 12.6 5.9 0.17
NAFLD, % 31.8 (n¼ 21) 70.7 (n¼ 29) <0.001
Sample size (n¼ 107).
Data are expressed as means  SD, medians, and IQR (in parenthesis), or relative and absolute proportions.
ALT¼ alanine aminotransferase, ARB¼ angiotensin receptor blocker, AST¼ aspartate aminotransferase, CHD¼ coronary heart disease,
eGFR¼ estimated glomerular filtration rate, GGT¼ gamma-glutamyltransferase, HF¼ heart failure, LV¼ left ventricular, NAFLD¼ nonalcoholic
Valbusa et al Medicine  Volume 95, Number 7, February 2016serum GGT levels >60U/L and ALT >30U/L (HR 2.66, 95%
CI 1.1–6.9,P¼ 0.02) or those with rehospitalization in the early
postdischarge period, that is, rehospitalizations at 1 month (HR
3.64, 95% CI 1.6–8.1, P¼ 0.001).
DISCUSSION
To our knowledge, this is the first prospective, observa-
tional study with the specific aim of establishing the prognostic
role of NAFLD in predicting 1-year all-cause rehospitalization
rates in a sample of well characterized patients hospitalized for
acute HF.
The major findings of our study were as follows: rehos-
pitalizations (almost 97% of cardiac etiology) occurred in 41/
nonalcoholic fatty liver disease.107 of the patients who were discharged after their first acute
HF admission, and the overall cumulative rates of all-cause
rehospitalization were 12.1% at 1 month, 25.2% at 3 months,
4 | www.md-journal.com29.9% at 6 months, and 38.3% at 1 year; 1-year re-hospitaliz-
ation rates were markedly higher in patients with NAFLD than
in those without NAFLD at baseline; and Cox regression
analysis revealed that NAFLD was associated with an approxi-
mately 5.5-fold increased risk of 1-year rehospitalization, inde-
pendently of multiple HF risk factors and potential confounders.
Notably, as shown in Figure 3, these results were consistent in all
subgroups evaluated. In particular, we found that NAFLD was
associated with higher 1-year rehospitalization rates in both men
and women, in those with and without preexisting CHD, in those
with and without established diabetes, in those with and without
atrial fibrillation, in those with reduced or normal eGFRMDRD
values, in those with higher or lower NT-proBNP levels, in those
with LV ejection fraction below or above 35%, and in those with
increased or normal serum liver enzyme levels.
The rates of 1-year rehospitalization we observed in this
study were similar to those reported by other investigators in
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Kaplan–Meier curves. Rates of 1-year all-cause rehos-
pitalization in patients with and without NAFLD who were hos-
FIGURE 3. Subgroup analyses. Associations between NAFLD and
Medicine  Volume 95, Number 7, February 2016 Fatty Liver and Heart Failure Rehospitalizationother cohorts of HF inpatients with comparable baseline charac-
teristics.2,15 As expected from reviewing the published litera-
ture, in our study, other variables independently associated with
higher 1-year rehospitalization rates were male sex, higher GGT
levels, and lower baseline eGFRMDRD. In fact, CKD and
worsening renal function have been associated with poor
clinical outcomes in HF patients.16–18 Decreased renal function
at the time of admission has also been found to be an indepen-
pitalized for acute HF patients at baseline. HF¼heart failure,
NAFLD¼nonalcoholic fatty liver disease.ent predictor of HF rehospitalization.2,16 Previous studies have
lso reported that severe HF is frequently associated with a
holestatic liver enzyme profile with elevated serum levels of
ABLE 2. Factors Independently Associated With 1-year All-
ause Rehospitalization Rates in Patients With Acute HF at
aseline
ox Hazard Models Hazard Ratio 95% CI P
AFLD (yes vs no)
Unadjusted model 3.71 1.88–7.30<0.001
Adjusted model 1 4.83 2.36–10.1<0.001
Adjusted model 2 5.38 2.55–11.2<0.001
Adjusted model 3 5.56 2.46–12.1<0.001
ther independent predictors of 1-year rehospitalization in adjusted
model 3
Male sex 3.58 1.61–8.33 0.001
eGFRMDRD (mL/min/1.73m
2) 0.98 0.96–0.99 <0.01
Serum GGT level (U/L) 1.02 1.01–1.03 <0.01
Sample size (n¼ 107).
Data are expressed as hazard ratios 95% confidence intervals (CIs)
s assessed by either univariable (unadjusted) or multivariable Cox
azard models.
Other covariates included in multivariable regression models, along
ith NAFLD, were as follows: model 1: age and sex; model 2: age, sex,
GFRMDRD, and serum GGT levels; model 3: adjustment for the same
ariables included in model 2 þ NT-proBNP levels, LV ejection
action, body mass index, diabetes status, and prior atrial fibrillation.d
a
c
T
c
B
C
N
O
a
h
w
e
v
fr
CI¼ confidence interval, eGFR¼ estimated glomerular filtration
rate, GGT¼ gamma-glutamyltransferase, NAFLD¼ nonalcoholic fatty
liver disease.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.GGT, bilirubin, and aminotransferases.1,2,19 More recently, in a
large sample of patients with chronic HF, serum GGT levels
have also been positively associated with disease severity and
with poor long-term outcomes (ie, death or heart transplan-
tation).20 At first glance, the lack of any independent association
between advancing age and 1-year rehospitalization rates could
seem unexpected. However, it is possible to assume that the lack
of any independent association between age and 1-year rehos-
pitalization in our dataset is likely to be due to the elevated mean
age (80 y) of our study participants.
Collectively, although this is a hypothesis-generating
study that requires further confirmation through future larger
prospective studies, our results suggest that the identification of
NAFLD in patients hospitalized for acute HF might help in risk
prediction of 1-year rehospitalizations with important manage-
ment implications. Identifying people with NAFLD would
highlight a subgroup of patients with acute HF, who should
be targeted with more intensive therapy to decrease their risk of
future hospital readmissions for HF-related causes.
An obvious caveat in interpreting the results of our study is
that abnormal levels of serum liver enzymes may be present in
patients with acute HF, possibly due either to the coexistence of
cardiac hepatopathy or to the use of some potentially hepato-
toxic drugs (such as amiodarone or warfarin). Cardiac hepato-
pathy describes any liver damage caused by cardiac disorders in
the absence of other possible causes of liver damage.19
Although there is no consensus on the terminology used, cardiac
hepatopathy can be subdivided into two forms: congestive
hepatopathy and cardiogenic ischemic hepatitis. Both of these
forms may have a prognostic value for identifying CHD death
and events. Congestive hepatopathy is caused by passive venous
congestion of the liver that generally occurs in the setting of
chronic cardiac conditions such as chronic HF, constrictive
pericarditis, tricuspid regurgitation, or right-sided HF of any
cause. Cardiogenic ischemic hepatitis is most commonly associ-
ated with acute cardiocirculatory failure, resulting from acute
1-year all-cause rehospitalization rates in patients hospitalized for
acute HF at baseline. HF¼heart failure, NAFLD¼nonalcoholic
fatty liver disease.myocardial infarction, or myocarditis. These 2 forms of cardiac
hepatopathy exhibit different histologic findings.19 In addition,
primary laboratory findings of congestive hepatopathy are
www.md-journal.com | 5
moderately elevated serum cholestasis markers (ie, GGT, bilir-
ubin, alkaline phosphatase), whereas cardiogenic ischemic
hepatitis typically exhibits a striking elevation in serum amino-
transferase and lactate dehydrogenase levels, mimicking acute
hepatitis of viral or toxic cause.19
That said, we believe that one of the most important
strength of our study was that the diagnosis of NAFLD was
based on ultrasonography (and not on abnormal serum liver
enzyme levels). This imaging method is usually able to differ-
entiate accurately hepatic venous congestion from fatty liver
deposition.21 We cannot, obviously, exclude that some of our
patients with ultrasonographic fatty liver and elevated serum
liver enzymes could also have a coexisting congestive hepato-
pathy. However, it is important to underline that the association
between NAFLD and 1-year rehospitalization rates remained
statistically significant even after excluding either those with
baseline abnormal serum GGT and aminotransferase levels, or
those with rehospitalizations in the early postdischarge period.
In addition, as shown in Table 1, it is also important to remark
that there were no significant differences in baseline LV ejec-
tion fraction and NT-proBNP levels between those with and
those without rehospitalization at follow-up, and that the use of
potentially hepatotoxic drugs, such as amiodarone and warfarin,
was either negligible or well comparable between the 2 groups
of patients. Unfortunately, an extensive ultrasonographic evalu-
ation of caval and suprahepatic veins to definitely exclude the
coexistence (in some cases) of congestive hepatopathy was not
routinely available in all patients. Nevertheless, we believe that
all the above-mentioned findings support the conclusion that the
majority of our patients had ultrasonographic fatty liver that was
preexisting to their first hospital admission and was likely due,
to a large extent, to concurrent NAFLD.
Although further research is needed to develop some
mechanistic clues, a number of putative pathophysiological
mechanisms can explain the significant association between
NAFLD and 1-year rehospitalization readmissions (mostly due
to cardiac causes) in patients with acute HF. There is now a
large body of evidence suggesting that NAFLD is not only
associated with an increased risk of CHD events,4–7 but is also
strongly associated with subclinical myocardial remodelling,
and an increase in cardiac output and LV filling pressures that
might lead to the development of clinical HF over time.8–11,22–
26 In addition, NAFLD is also associated with increased left
atrial volume,11,26 and some studies have shown that NAFLD
patients have an increased prevalence and incidence of atrial
fibrillation, an established risk factor of HF, compared with
their counterparts without NAFLD.27–30 Finally, accumulating
experimental evidence also indicates that NAFLD is associated
with systemic/hepatic insulin resistance, myocardial lipid
toxicity, and systemic release of a variety of proinflammatory,
procoagulant, and proibrogenic mediators that play important
roles in the pathogenesis of both CHD and other functional,
structural, and arrhythmic complications of the heart.4–7,31,32
Collectively, these findings strongly suggest that NAFLD
patients may benefit from more intensive surveillance and early
treatment interventions to decrease the risk for HF and its major
complications, including subsequent hospital readmissions.
Our study has some limitations that should be mentioned.
Firstly, this study is limited by a relatively small sample size and
its observational design. Although the study works with longi-
tudinal data, its observational character does not permit to draw
Valbusa et alany firm conclusions on causal relationships. Secondly, the
diagnosis of NAFLD was based on ultrasound imaging and the
exclusion of secondary causes of chronic liver diseases, but was
6 | www.md-journal.comnot confirmed by liver biopsy that is considered the ‘‘gold
standard’’ for the diagnosis of NAFLD and its more progressive
forms, such as nonalcoholic steatohepatitis (NASH). However,
we believe that it would be hazardous to perform a liver biopsy
in these patients hospitalized for acute HF, who had normal or
only moderately elevated levels of serum liver enzymes. Indeed,
liver ultrasonography allows for reliable and accurate detection
of moderate fatty liver, compared with histology. Because of its
low cost, safety, and accessibility, ultrasonography is interna-
tionally recommended as the first-line imaging modality for
diagnosing fatty liver in clinical practice.33 Thirdly, although
our statistical models were extensive, unmeasured confounders
could partially explain the observed associations. Finally,
because our sample comprised white patients who were
admitted for acute HF in a single hospital center, our results
may not necessarily be generalizable to other groups of hospi-
talized patients with acute HF of different ethnicity.
Notwithstanding these limitations, the major strengths of
our study include the ultrasonographic diagnosis of NAFLD, the
complete nature of the dataset, and the ability to adjust for
several HF risk factors and potential confounders.
CONCLUSIONS
These results indicate that NAFLD as detected by
ultrasonography was independently associated with higher
1-year rehospitalization rates among patients hospitalized for
acute HF. Further studies in larger cohorts of patients with
acute HF are needed to confirm the reproducibility of these
results and to better elucidate the putative mechanisms
underlying this association.
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